Pub Date : 2025-12-01Epub Date: 2025-10-29DOI: 10.1016/j.semerg.2025.102581
C. Muñoz-Pindado , R. Bonich-Juan , C. Muñoz-Pindado , P. Roura-Poch , E. Puigoriol-Juvanteny , S. Sánchez-Belmonte , M. Palomanes-Atanes , A.M. Rovira-Cruells , F. Ruiz-Mori , C. Serra , M. Dalmases , L. Barranco-Cózar , A. Zorrilla-Barranco , S. Serra-Carreras , L.R. Collado-Yurrita , N. Roger-Casals
Objectives
To assess the usefulness of the Epworth (ESS), Berlin, and STOP-Bang (SB) screening tools, combined with the Apnealink™ device (AL), in collaboration with the USH, in diagnosing OSA with AHI ≥ 5/h or moderate-to-severe OSA (IAH ≥ 15/h).
Material and methods
The study included patients aged 18 to 80 years with suspected OSA and a SB score ≥ 3. Patients were initially assessed by a primary care physician (PCP) using the AL device and subsequently evaluated by the USH. Collected data included anthropometric measurements, personal medical history, clinical characteristics related to OSA, screening tool scores, AL study results, PGR findings, diagnostic and therapeutic decisions made by the PCP, and confirmatory assessments by the USH. All data were entered into a computerized system for statistical analysis. The study analyzed both the overall sample and gender-specific subgroups. The effectiveness of the screening tools was assessed through ROC curve analysis.
Results
The study included 150 patients (97 men, 53 women) with a mean age of 56 ± 12.37 years. Significant gender differences were observed: men had higher values for weight, height, BMI ≥ 35, neck circumference, waist circumference, waist-to-hip ratio, elevated neck circumference (> 43 cm in men, > 41 cm in women), high SB score (≥ 5), and higher tobacco and alcohol consumption.
A total of 144 patients underwent AL testing, with 133 patients having an AHI > 5/h and 98 patients an AHI ≥ 15/h. The agreement with the USH was 89%, with a K = 0.88 ± 0.036 (95% CI: 0.8-0.94, P < .001).
According to the screening tools, the probability of having OSA with AHI ≥ 5/h was: SB-AUC = 0.63 ± 0.08 (95% CI: 0.047-0.78, P = .098). For AHI ≥ 15/h: SB-AUC = 0.77 ± 0.04 (95% CI: 0.048-0.92, P = 0.080), Berlin-AUC = 0.55 ± 0.05 (95% CI: 0.45-0.66, P = .305), ESS-AUC = 0.49 ± 0.05 (95% CI: 0.039-0.59, P = .889).
Conclusions
The SB tool demonstrated the best performance. The use of screening tools combined with simple diagnostic methods in primary care, in collaboration with USH, is both feasible and cost-effective for managing OSA in our setting.
{"title":"Utilidad diagnóstica de las herramientas de cribado (escala Epworth, cuestionario de Berlín y cuestionario STOP-Bang) en la apnea obstructiva de sueño moderada-grave apoyados por métodos de diagnóstico sencillos domiciliarios en atención primaria","authors":"C. Muñoz-Pindado , R. Bonich-Juan , C. Muñoz-Pindado , P. Roura-Poch , E. Puigoriol-Juvanteny , S. Sánchez-Belmonte , M. Palomanes-Atanes , A.M. Rovira-Cruells , F. Ruiz-Mori , C. Serra , M. Dalmases , L. Barranco-Cózar , A. Zorrilla-Barranco , S. Serra-Carreras , L.R. Collado-Yurrita , N. Roger-Casals","doi":"10.1016/j.semerg.2025.102581","DOIUrl":"10.1016/j.semerg.2025.102581","url":null,"abstract":"<div><h3>Objectives</h3><div>To assess the usefulness of the Epworth (ESS), Berlin, and STOP-Bang (SB) screening tools, combined with the Apnealink™ device (AL), in collaboration with the USH, in diagnosing OSA with AHI<!--> <!-->≥<!--> <!-->5/h or moderate-to-severe OSA (IAH<!--> <!-->≥<!--> <!-->15/h).</div></div><div><h3>Material and methods</h3><div>The study included patients aged 18 to 80<!--> <!-->years with suspected OSA and a SB score ≥<!--> <!-->3. Patients were initially assessed by a primary care physician (PCP) using the AL device and subsequently evaluated by the USH. Collected data included anthropometric measurements, personal medical history, clinical characteristics related to OSA, screening tool scores, AL study results, PGR findings, diagnostic and therapeutic decisions made by the PCP, and confirmatory assessments by the USH. All data were entered into a computerized system for statistical analysis. The study analyzed both the overall sample and gender-specific subgroups. The effectiveness of the screening tools was assessed through ROC curve analysis.</div></div><div><h3>Results</h3><div>The study included 150 patients (97<!--> <!-->men, 53<!--> <!-->women) with a mean age of 56<!--> <!-->±<!--> <!-->12.37<!--> <!-->years. Significant gender differences were observed: men had higher values for weight, height, BMI<!--> <!-->≥<!--> <!-->35, neck circumference, waist circumference, waist-to-hip ratio, elevated neck circumference (><!--> <!-->43<!--> <!-->cm in men, ><!--> <!-->41<!--> <!-->cm in women), high SB score (≥<!--> <!-->5), and higher tobacco and alcohol consumption.</div><div>A total of 144 patients underwent AL testing, with 133 patients having an AHI<!--> <!-->><!--> <!-->5/h and 98 patients an AHI<!--> <!-->≥<!--> <!-->15/h. The agreement with the USH was 89%, with a K<!--> <!-->=<!--> <!-->0.88<!--> <!-->±<!--> <!-->0.036 (95%<!--> <!-->CI: 0.8-0.94, <em>P</em> <!--><<!--> <!-->.001).</div><div>According to the screening tools, the probability of having OSA with AHI<!--> <!-->≥<!--> <!-->5/h was: SB-AUC<!--> <!-->=<!--> <!-->0.63<!--> <!-->±<!--> <!-->0.08 (95%<!--> <!-->CI: 0.047-0.78, <em>P</em> <!-->=<!--> <!-->.098). For AHI<!--> <!-->≥<!--> <!-->15/h: SB-AUC<!--> <!-->=<!--> <!-->0.77<!--> <!-->±<!--> <!-->0.04 (95%<!--> <!-->CI: 0.048-0.92, <em>P</em> <!-->=<!--> <!-->0.080), Berlin-AUC<!--> <!-->=<!--> <!-->0.55<!--> <!-->±<!--> <!-->0.05 (95%<!--> <!-->CI: 0.45-0.66, <em>P</em> <!-->=<!--> <!-->.305), ESS-AUC<!--> <!-->=<!--> <!-->0.49<!--> <!-->±<!--> <!-->0.05 (95%<!--> <!-->CI: 0.039-0.59, <em>P</em> <!-->=<!--> <!-->.889).</div></div><div><h3>Conclusions</h3><div>The SB tool demonstrated the best performance. The use of screening tools combined with simple diagnostic methods in primary care, in collaboration with USH, is both feasible and cost-effective for managing OSA in our setting.</div></div>","PeriodicalId":53212,"journal":{"name":"Medicina de Familia-SEMERGEN","volume":"51 9","pages":"Article 102581"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-21DOI: 10.1016/j.semerg.2025.102573
F.L. Moya
{"title":"Primer contacto y primera fotocopia","authors":"F.L. Moya","doi":"10.1016/j.semerg.2025.102573","DOIUrl":"10.1016/j.semerg.2025.102573","url":null,"abstract":"","PeriodicalId":53212,"journal":{"name":"Medicina de Familia-SEMERGEN","volume":"51 9","pages":"Article 102573"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145349778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-22DOI: 10.1016/j.semerg.2025.102579
M. AlaaEldein Elsuity , F.A. Butt , K. Saeed Khan , M. Fawzy , M. Martín-Díaz , P.F.W. Chien , J. Perez de Rojas , M. Núñez-Núñez , M.M. Rashwan , A. Bueno-Cavanillas
Objectives
This scoping systematic review aimed to collate and synthesize available evidence on research ethics and consent aspects related to research integrity standards in RCTs. Prospective registration (https://osf.io/gxryb).
Materials and methods
We searched PubMed and Scopus databases from January 2018 to August 2023, using combinations of terms related to research ethics, approval, and informed consent. We included full academic articles relevant to the scope of the review without language restriction, including primary research articles, systematic reviews, scoping reviews, and narrative reviews. Two teams of four reviewers independently assessed the full text to select articles and extract data, performing the tasks independently and any disagreements were resolved through arbitration. A descriptive synthesis of the included articles main characteristics and findings were performed.
Results
Sixty-nine articles were selected, covering RCT-related ethics and consent issues in 141 countries, including 89 (63%) low or middle-income ones. The extracted data fell into nine domains: general issues (30 articles; 43%), journals’ instructions and policies (one article; 1.4%), research institutions and funders’ policies (three articles; 4.3%), ethics committee regulations (five articles; 7.2%), ethics committee evaluation and approval (12 articles; 17%), informed consent and related procedures (six articles; 8.7%), monitoring of trials for compliance (three articles; 4.3%), post-publication concerns on ethics and consent (five articles; 7.2%), and recommendations for future research (four articles; 5.8%).
Conclusions
The key areas include standardization of ethics committee approval processes and enhancement of informed consent procedures. There were notable deficiencies in trial registration and reporting concerning ethics and consent. The observed variability in ethics and consent practices across RCTs globally needs to be addressed through an international expert consensus.
{"title":"Ethics and consent in randomized clinical trial integrity: A scoping systematic review","authors":"M. AlaaEldein Elsuity , F.A. Butt , K. Saeed Khan , M. Fawzy , M. Martín-Díaz , P.F.W. Chien , J. Perez de Rojas , M. Núñez-Núñez , M.M. Rashwan , A. Bueno-Cavanillas","doi":"10.1016/j.semerg.2025.102579","DOIUrl":"10.1016/j.semerg.2025.102579","url":null,"abstract":"<div><h3>Objectives</h3><div>This scoping systematic review aimed to collate and synthesize available evidence on research ethics and consent aspects related to research integrity standards in RCTs. Prospective registration (<span><span>https://osf.io/gxryb</span><svg><path></path></svg></span>).</div></div><div><h3>Materials and methods</h3><div>We searched PubMed and Scopus databases from January 2018 to August 2023, using combinations of terms related to research ethics, approval, and informed consent. We included full academic articles relevant to the scope of the review without language restriction, including primary research articles, systematic reviews, scoping reviews, and narrative reviews. Two teams of four reviewers independently assessed the full text to select articles and extract data, performing the tasks independently and any disagreements were resolved through arbitration. A descriptive synthesis of the included articles main characteristics and findings were performed.</div></div><div><h3>Results</h3><div>Sixty-nine articles were selected, covering RCT-related ethics and consent issues in 141 countries, including 89 (63%) low or middle-income ones. The extracted data fell into nine domains: general issues (30 articles; 43%), journals’ instructions and policies (one article; 1.4%), research institutions and funders’ policies (three articles; 4.3%), ethics committee regulations (five articles; 7.2%), ethics committee evaluation and approval (12 articles; 17%), informed consent and related procedures (six articles; 8.7%), monitoring of trials for compliance (three articles; 4.3%), post-publication concerns on ethics and consent (five articles; 7.2%), and recommendations for future research (four articles; 5.8%).</div></div><div><h3>Conclusions</h3><div>The key areas include standardization of ethics committee approval processes and enhancement of informed consent procedures. There were notable deficiencies in trial registration and reporting concerning ethics and consent. The observed variability in ethics and consent practices across RCTs globally needs to be addressed through an international expert consensus.</div></div>","PeriodicalId":53212,"journal":{"name":"Medicina de Familia-SEMERGEN","volume":"51 9","pages":"Article 102579"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lecciones aprendidas de un caso de diabetes MODY mal diagnosticado: implicaciones para la práctica clínica","authors":"J. Nicolás Cordero , R.D. Labrada Reyes , M.I. Peña Cano , M.G. Berumen Lechuga","doi":"10.1016/j.semerg.2025.102620","DOIUrl":"10.1016/j.semerg.2025.102620","url":null,"abstract":"","PeriodicalId":53212,"journal":{"name":"Medicina de Familia-SEMERGEN","volume":"51 9","pages":"Article 102620"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-11-11DOI: 10.1016/j.semerg.2025.102628
B. Ahmad , P. Kumar Singh , R.J. Shah , M. Hammad Arif , A. Goel , M. Saeed , A. Omar Saleh , S.E. Amer , M. Mukhlis , S. Ahmed Waqas , R. Ahmed
Aim
Glucagon-like peptide-1 receptor agonists (GLP-1RA) may play a role in improving quality of life and improving long-term outcomes in heart failure with preserved ejection fraction (HFpEF) patients. We conducted a systematic review and meta-analysis evaluating the safety and efficacy of GLP-1RA in HFpEF patients.
Methods
A systematic search strategy was developed using databases, namely PubMed, Web of Science, Cochrane, and Clinicaltrials.gov. The primary outcomes analyzed were hospitalisation events, MACE, and quality of life parameters, i.e., Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), 6-minute walk distance (6MWD). Review Manager and RStudio were employed for the statistical analysis, utilizing the random effects model with pre-defined effect measures.
Results
We identified six randomized controlled trials (RCTs) and four observational studies in our meta-analysis, with a total of 108,634 patients. Hospitalization due to heart failure was reduced notably by 37% (HR 0.63; 95% CI: 0.54–0.72), and MACE events favoured GLP-1RA by HR of 0.73 (95% CI: 0.61–0.88; p = 0.0008). We found a significant improvement with GLP-1RA therapy in KCCQ-CSS scores (MD 8.55, 95% CI: 6.78–10.29; p < 0.00001) and 6MWD (MD 15.90, 95% CI: 15.35–16.46; p < 0.00001). Regarding safety outcomes, a significant increase in GI effects (RR 1.56; 95% CI: 1.39–1.75; p < 0.00001), and a lower risk of arrhythmias (RR 0.84; 95% CI: 0.79–0.90; p < 0.0001).
Conclusion
GLP-1RA yields significant advantages in HFpEF patients, including enhanced quality of life, valuable weight loss, reduced heart biomarkers, and a decrease in heart failure hospitalizations. Regardless of elevated GI side effects, the GLP-1RAs act as encouraging therapeutic alternatives in HFpEF.
{"title":"Glucagon-like peptide-1 receptor agonists for improving quality of life and mortality in adults with heart failure with preserved ejection fraction: A systematic review and meta-analysis of efficacy and safety","authors":"B. Ahmad , P. Kumar Singh , R.J. Shah , M. Hammad Arif , A. Goel , M. Saeed , A. Omar Saleh , S.E. Amer , M. Mukhlis , S. Ahmed Waqas , R. Ahmed","doi":"10.1016/j.semerg.2025.102628","DOIUrl":"10.1016/j.semerg.2025.102628","url":null,"abstract":"<div><h3>Aim</h3><div>Glucagon-like peptide-1 receptor agonists (GLP-1RA) may play a role in improving quality of life and improving long-term outcomes in heart failure with preserved ejection fraction (HFpEF) patients. We conducted a systematic review and meta-analysis evaluating the safety and efficacy of GLP-1RA in HFpEF patients.</div></div><div><h3>Methods</h3><div>A systematic search strategy was developed using databases, namely PubMed, Web of Science, Cochrane, and Clinicaltrials.gov. The primary outcomes analyzed were hospitalisation events, MACE, and quality of life parameters, i.e., Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), 6-minute walk distance (6MWD). Review Manager and RStudio were employed for the statistical analysis, utilizing the random effects model with pre-defined effect measures.</div></div><div><h3>Results</h3><div>We identified six randomized controlled trials (RCTs) and four observational studies in our meta-analysis, with a total of 108,634 patients. Hospitalization due to heart failure was reduced notably by 37% (HR 0.63; 95% CI: 0.54–0.72), and MACE events favoured GLP-1RA by HR of 0.73 (95% CI: 0.61–0.88; <em>p</em> <!-->=<!--> <!-->0.0008). We found a significant improvement with GLP-1RA therapy in KCCQ-CSS scores (MD 8.55, 95% CI: 6.78–10.29; <em>p</em> <!--><<!--> <!-->0.00001) and 6MWD (MD 15.90, 95% CI: 15.35–16.46; <em>p</em> <!--><<!--> <!-->0.00001). Regarding safety outcomes, a significant increase in GI effects (RR 1.56; 95% CI: 1.39–1.75; <em>p</em> <!--><<!--> <!-->0.00001), and a lower risk of arrhythmias (RR 0.84; 95% CI: 0.79–0.90; <em>p</em> <!--><<!--> <!-->0.0001).</div></div><div><h3>Conclusion</h3><div>GLP-1RA yields significant advantages in HFpEF patients, including enhanced quality of life, valuable weight loss, reduced heart biomarkers, and a decrease in heart failure hospitalizations. Regardless of elevated GI side effects, the GLP-1RAs act as encouraging therapeutic alternatives in HFpEF.</div></div>","PeriodicalId":53212,"journal":{"name":"Medicina de Familia-SEMERGEN","volume":"51 9","pages":"Article 102628"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145508096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-11-15DOI: 10.1016/j.semerg.2025.102629
M. Gómez Manzanares, O. Al-wattar Ceballos, M. García Arpa
{"title":"Foliculitis del jacuzzi: cuando la clave está en la historia clínica","authors":"M. Gómez Manzanares, O. Al-wattar Ceballos, M. García Arpa","doi":"10.1016/j.semerg.2025.102629","DOIUrl":"10.1016/j.semerg.2025.102629","url":null,"abstract":"","PeriodicalId":53212,"journal":{"name":"Medicina de Familia-SEMERGEN","volume":"51 9","pages":"Article 102629"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145528352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-11-08DOI: 10.1016/j.semerg.2025.102614
J.I. Martínez Ortega , T.K. Medina Angulo , I. Fernández Reyna
{"title":"Tiña facial de origen zoonótico por Microsporum canis en paciente pediátrico","authors":"J.I. Martínez Ortega , T.K. Medina Angulo , I. Fernández Reyna","doi":"10.1016/j.semerg.2025.102614","DOIUrl":"10.1016/j.semerg.2025.102614","url":null,"abstract":"","PeriodicalId":53212,"journal":{"name":"Medicina de Familia-SEMERGEN","volume":"51 9","pages":"Article 102614"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145483714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-11-17DOI: 10.1016/j.semerg.2025.102640
A. Gotor-Rivera , B. Joven-Ibáñez , R. Rivera-Díaz , A. Blanco-Echevarría
Psoriasis is a chronic inflammatory disease associated with an increase in vascular risk, both for the higher prevalence of traditional risk factors as for the systemic inflammatory milieu. This risk is particularly increased in patients with moderate-to-severe psoriasis or psoriatic arthritis. Several studies have highlighted underdiagnosis and suboptimal control of hypertension, dyslipidaemia, diabetes and obesity in this population. Early and structured screening allows identification of patients with a high vascular risk eligible for intervention, being primary care the optimal area due to its accessibility and experience in cardiovascular prevention. Nevertheless, higher awareness about the association between psoriasis and vascular risk among physicians is required, as well as an adaptation of existing screening strategies to the individual characteristics of each patient, especially among cases with a higher inflammatory load. A proactive approach could potentially improve quality of life and life expectancy among patients with psoriasis.
{"title":"Manejo del riesgo vascular en pacientes con psoriasis en atención primaria","authors":"A. Gotor-Rivera , B. Joven-Ibáñez , R. Rivera-Díaz , A. Blanco-Echevarría","doi":"10.1016/j.semerg.2025.102640","DOIUrl":"10.1016/j.semerg.2025.102640","url":null,"abstract":"<div><div>Psoriasis is a chronic inflammatory disease associated with an increase in vascular risk, both for the higher prevalence of traditional risk factors as for the systemic inflammatory milieu. This risk is particularly increased in patients with moderate-to-severe psoriasis or psoriatic arthritis. Several studies have highlighted underdiagnosis and suboptimal control of hypertension, dyslipidaemia, diabetes and obesity in this population. Early and structured screening allows identification of patients with a high vascular risk eligible for intervention, being primary care the optimal area due to its accessibility and experience in cardiovascular prevention. Nevertheless, higher awareness about the association between psoriasis and vascular risk among physicians is required, as well as an adaptation of existing screening strategies to the individual characteristics of each patient, especially among cases with a higher inflammatory load. A proactive approach could potentially improve quality of life and life expectancy among patients with psoriasis.</div></div>","PeriodicalId":53212,"journal":{"name":"Medicina de Familia-SEMERGEN","volume":"51 9","pages":"Article 102640"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145551864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号